Study of Minocycline Treatment for Chronic Autoimmune Uveitis and Retinal Degeneration in Adults

What this Trial Is About

Researchers are evaluating minocycline for chronic autoimmune uveitis, a serious non-infectious eye disease that can cause blindness due to ongoing inflammation and damage to eye structures. Current treatments like glucocorticoids, immunosuppressants, and biologics have limited success in managing this persistent condition. This trial aims to assess the effectiveness and safety of minocycline, which has shown immune-modulating and anti-apoptosis properties in other neuro-inflammatory diseases. Participants in this interventional study will take a daily oral dose of 100 mg minocycline capsules. The trial focuses on monitoring changes in eye function and structure over 6 and 12 months. Key measurements include macular sensitivity, best-corrected visual acuity BCVA, visual field, and photopic and scotopic response changes. An evaluation of macular vessels, contrast sensitivity, color vision, and quality of life will also be conducted, along with tracking ocular and non-ocular adverse events. During the study, participants will undergo regular exams to assess vision and eye health, including tests for visual acuity, visual field, and retinal responses. Quality of life questionnaires will be collected at 6 and 12 months. Safety will be monitored through adverse event reporting and clinical assessments. Overall participation may last at least one year, with evaluations at these key time points to understand minocyclines impact on chronic autoimmune uveitis and retinal degeneration.

Minocycline for Chronic Autoimmune Uveitis